US EditionPublished • loading... • Updated
France-Based Phagos Lands $29m to Further Develop Its Antibiotic Alternative for Livestock
Summary by AgFunderNews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
France-based Phagos lands $29m to further develop its antibiotic alternative for livestock
Paris, France-based biotech company Phagos has raised a €25 million ($29 million) Series A round to further develop its bacteriophage drugs used to treat bacterial disease in animals and, eventually, humans. The company calls these drugs “a sustainable answer to the global challenge of bacterial resistance.” It will use the funding to deploy treatments, starting with animal health, as well as further develop its technology that simplifies the di…
L'article Biotech Phagos raises 25 million euros to eradicate bacterial diseases est apparu en premier sur Maddyness - Le média pour comprendre le économie demain.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
